Enoxaparin
Loading...
Date
Authors
Padayachee, N.
Schoeman, N.
Schellack, Natalie
Journal Title
Journal ISSN
Volume Title
Publisher
Medpharm Publications
Abstract
The development of low-molecular and ultra-low-molecular weight heparins has changed anticoagulation treatment options. Enoxaparin is a low-molecular weight heparin (LMWH), which works on Factor Xa and is indicated for both the prevention and treatment of various thrombotic conditions. Dosing is individualised to patient and condition. There is uncertainty about the dose in obese patients, with no clear consensus on an appropriate dose. COVID-19-associated coagulopathy has resulted in the investigation of enoxaparin to help reduce mortality.
Description
Keywords
Enoxaparin, Coagulopathy, Factor Xa, Low-molecular weight heparin (LMWH), COVID-19 pandemic, Coronavirus disease 2019 (COVID-19), Thrombotic conditions
Sustainable Development Goals
Citation
Padayachee N., Schoeman N. & Schellack, N. 2021, 'Enoxaparin', SA Pharmaceutical Journal, vol. 88, no. 2, pp. 26-29, doi : 10.10520/ejc-mp_sapj_v88_n2_a7.